Form 8-K

8-K — CNS Pharmaceuticals, Inc.

Accession: 0001683168-26-007552

Filed: 2026-10-02

Period: 2026-09-30

CIK: 0001729427

SIC: 2834 (PHARMACEUTICAL PREPARATIONS)

Item: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Item: Submission of Matters to a Vote of Security Holders

Item: Financial Statements and Exhibits

Documents

8-K — cns_8k.htm (Primary)

EX-10.1 — CNS PHARMACEUTICALS, INC. 2020 EQUITY PLAN (cns_ex1001.htm)

XML — IDEA: XBRL DOCUMENT (R1.htm)

8-K — FORM 8-K

8-K (Primary)

Filename: cns_8k.htm · Sequence: 1

8-K

false

0001729427

2026-09-30

iso4217:USD

xbrli:shares

iso4217:USD

xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

___________________________

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of Report (Date of earliest event reported):

September 30, 2026

___________________________

CNS Pharmaceuticals, Inc.

(Exact name of registrant as specified in its

charter)

___________________________

Nevada

001-39126

82-2318545

(State or other jurisdiction of

incorporation or organization)

(Commission File Number)

(I.R.S. Employer Identification No.)

2100 West Loop South, Suite 900

Houston, Texas 77027

(Address of principal executive offices)

(Zip Code)

Registrant’s telephone number, including

area code: (800) 946-9185

Not Applicable

(Former Name or Former Address, if Changed

Since Last Report)

___________________________

Check the appropriate

box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following

provisions (see General Instruction A.2. below):

☐ Written

communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting

material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement

communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement

communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth

company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange

Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by

check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting

standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Securities registered pursuant to Section

12(b) of the Act:

Title of each class

Trading Symbols(s)

Name of each exchange on which registered

Common stock, par value $0.001 per share

CNSP

The NASDAQ Stock Market LLC

Item 5.02 Departure of Directors or Certain

Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

As reported below under

Item 5.07 of this Current Report, CNS Pharmaceuticals, Inc. (the “Company”) held its scheduled 2026 Annual Meeting of Stockholders

(the “Annual Meeting”) at which the Company’s stockholders approved amendments to the Company's 2020 Equity Plan (the

“2020 Plan”) including an increase in the number of shares of common stock, par value $0.001 per share, authorized for issuance

under the 2020 Plan by 650,000 shares. As amended, the number of shares of the common stock that may be issued under the 2020 Plan is

765,061 shares (this includes the 650,000 share increase).

For more information

about the 2020 Plan and amendments thereto, see the Company’s definitive proxy statement filed with the U.S. Securities and Exchange

Commission on August 21, 2026 (the “Proxy Statement”), the relevant portions

of which are incorporated herein by reference. The foregoing description of the amendments to the 2020 Plan does not purport to be complete

and is qualified in its entirety by reference to the complete text of the 2020 Plan, as amended, a copy of which is filed as Exhibit 10.1

to this Current Report and is incorporated herein by reference.

Item 5.07 Submission

of Matters to a Vote of Security Holders.

The Company

held its Annual Meeting at 12:00 p.m. ET on September 30, 2026. As of August 10, 2026, the

record date for the Annual Meeting, there were 1,461,449 shares of common stock issued and

outstanding and entitled to vote on the proposals presented at the Annual Meeting, of which 668,188, or 45.72%, were present in person

or represented by proxy, which constituted a quorum. The holders of shares of Company common stock are entitled to one vote for each share

held. Set forth below are the final voting results for each of the proposals submitted to a vote of the Company's stockholders at the

Annual Meeting.

The proposals

are described in detail in the Company’s Proxy Statement, the relevant portions of which are incorporated herein by reference.

Proposal 1. Election of Directors –

The Company’s stockholders elected Faith Charles, Bettina Cockroft, Michal Fisher, Jeffrey Keyes, Rami Levin and Amy Mahery, as

directors of the Company until the Company’s 2027 Annual Meeting of Stockholders, or until their respective successors have been

duly elected and qualified, by the following vote:

Director

Votes For

Votes Withheld

Broker Non-Votes

Faith Charles

101,003

4,113

563,072

Bettina Cockroft

102,445

2,671

563,072

Michal Fisher

102,460

2,656

563,072

Jeffrey Keyes

100,524

4,592

563,072

Rami Levin

102,434

2,682

563,072

Amy Mahery

101,295

3,821

563,072

Proposal 2. Ratification of

Appointment of Independent Registered Public Accounting Firm - The Company's stockholders ratified the appointment of MaloneBailey,

LLP as the Company's independent registered public accounting firm for the year ending December 31, 2026, by the following vote:

Votes For

Votes Against

Abstain

Broker Non-Votes

637,228

30,874

Proposal

3. Executive Compensation – The Company’s stockholders approved a resolution approving, on an advisory basis, the compensation

paid to the Company’s executive officers, by the following vote:

Votes For

Votes Against

Abstain

Broker Non-Votes

98,103

6,682

331

563,072

Proposal

4. Amendment to 2020 Equity Plan Approval - The Company’s stockholders approved amendments to the 2020 Plan including an increase

in the number of shares of common stock authorized for issuance by 650,000 shares under the 2020 Plan, by the following vote:

Votes For

Votes Against

Abstain

Broker Non-Votes

96,953

8,128

563,072

Proposal

5. To Authorize an Adjournment of the Annual Meeting - The Company’s stockholders authorized

the adjournment of the Annual Meeting, if necessary, to solicit additional proxies if there are not sufficient votes at the time of the

Annual Meeting or adjournment or postponement thereof to approve any of the above proposals, by the following vote:

Votes For

Votes Against

Abstain

Broker Non-Votes

622,421

45,635

132

Item 9.01. Financial Statements

and Exhibits.

(d) Exhibits.

No.

Description

10.1

CNS Pharmaceuticals, Inc. 2020 Equity Plan (as amended and restated)

104

Cover Page Interactive Data File (embedded within the Inline XBRL

document)

Signature

Pursuant

to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by

the undersigned hereunto duly authorized.

CNS Pharmaceuticals, Inc.

By:

/s/ Rami Levin

Rami Levin

Chief Executive Officer and President

Dated: October 1, 2026

EX-10.1 — CNS PHARMACEUTICALS, INC. 2020 EQUITY PLAN

EX-10.1

Filename: cns_ex1001.htm · Sequence: 2

Exhibit 10.1

CNS PHARMACEUTICALS, INC.

2020 EQUITY PLAN

(Amended and Restated)

______________________

Section 1.

Establishment and Purpose.

1.1 The Board of Directors

of CNS Pharmaceuticals, Inc. (the “Company”) established the CNS Pharmaceuticals, Inc. 2020 Equity Plan (the “Plan”)

effective as of April 6, 2020, which was approved by the Company’s stockholders at the Company’s annual meeting on June 8,

2020. The Plan was amended effective as of August 9, 2023, as of March 26, 2024, and on November 17, 2025 and on September 30, 2026, subject

to approval by the Company’s stockholders at the Company’s annual meeting on September 30, 2026.

1.2 The purpose of the Plan

is to attract and retain outstanding individuals as Key Employees, Directors and Consultants of the Company and its Subsidiaries, to recognize

the contributions made to the Company and its Subsidiaries by Key Employees, Directors and Consultants, and to provide such Key Employees,

Directors and Consultants with additional incentive to expand and improve the profits and achieve the objectives of the Company and its

Subsidiaries, by providing such Key Employees, Directors and Consultants with the opportunity to acquire or increase their proprietary

interest in the Company through receipt of Awards.

Section 2.

Definitions.

As used in the Plan, the following

terms shall have the meanings set forth below:

2.1 “Award” means

any award or benefit granted under the Plan, which shall be a Stock Option, a Stock Award, a Stock Unit Award or an SAR.

2.2 “Award Agreement”

means, as applicable, a Stock Option Agreement, Stock Award Agreement, Stock Unit Award Agreement or SAR Agreement evidencing an Award

granted under the Plan.

2.3 “Board”

means the Board of Directors of the Company.

2.4 “Change in Control”

has the meaning set forth in Section 8.2 of the Plan.

2.5 “Code”

means the Internal Revenue Code of 1986, as amended from time to time.

2.6 “Committee”

means the Compensation Committee of the Board or such other committee as may be designated by the Board from time to time to administer

the Plan, or, if no such committee has been designated at the time of any grants, it shall mean the Board.

2.7 “Common Stock”

means the Common Stock, par value $0.001 per share, of the Company.

2.8 “Company”

means CNS Pharmaceuticals, Inc., a Nevada corporation.

2.9 “Consultant”

means any person, including an advisor, who is engaged by the Company or an affiliate to render consulting or advisory services and is

compensated for such services. However, service solely as a Director, or payment of a fee for such service, will not cause a Director

to be considered a “Consultant” for purposes of the Plan. Notwithstanding the foregoing, a person is treated as a Consultant

under this Plan only if a Form S-8 Registration Statement under the Securities Act is available to register either the offer or the sale

of the Company’s securities to such person.

2.10 “Director”

means a director of the Company who is not an employee of the Company or a Subsidiary.

2.11 “Exchange Act”

means the Securities Exchange Act of 1934, as amended from time to time.

2.12 “Fair Market

Value” means as of any date, the closing price of a share of Common Stock on the national securities exchange on which the Common

Stock is listed, or, if the Common Stock is not listed on a national securities exchange, the over-the-counter market on which the Common

Stock trades, or, if the Common Stock is not listed on a national securities exchange or an over-the-counter market, as determined by

the Board as of such date, or, if no trading occurred on such date, as of the trading day immediately preceding such date.

2.13 “Incentive Stock

Option” or “ISO” means a Stock Option granted under Section 5 of the Plan that meets the requirements of

Section 422(b) of the Code or any successor provision.

2.14 “Key Employee”

means an employee of the Company or any Subsidiary selected to participate in the Plan in accordance with Section 3. A Key Employee may

also include a person who is granted an Award (other than an Incentive Stock Option) in connection with the hiring of the person prior

to the date the person becomes an employee of the Company or any Subsidiary, provided that such Award shall not vest prior to the commencement

of employment.

2.15 “Non-Qualified

Stock Option” or “NSO” means a Stock Option granted under Section 5 of the Plan that is not an Incentive

Stock Option.

2.16 “Participant”

means a Key Employee, Director or Consultant selected to receive an Award under the Plan.

2.17 “Plan”

means the CNS Pharmaceuticals, Inc. 2020 Equity Plan.

2.18 “Stock Appreciation

Right” or “SAR” means a grant of a right to receive shares of Common Stock or cash under Section 8 of the

Plan.

2.19 “Stock Award”

means a grant of shares of Common Stock under Section 6 of the Plan.

2.20 “Stock Option”

means an Incentive Stock Option or a Non-Qualified Stock Option granted under Section 5 of the Plan.

2.21 “Stock Unit

Award” means a grant of a right to receive shares of Common Stock or cash under Section 7 of the Plan.

2.22 “Subsidiary”

means an entity of which the Company is the direct or indirect beneficial owner of not less than 50% of all issued and outstanding equity

interest of such entity.

Section 3.

Administration.

3.1 The Committee.

The Plan shall be administered

by the Committee, which shall be comprised of at least two members of the Board who satisfy the “non-employee director” definition

set forth in Rule 16b-3 under the Exchange Act, unless the Board otherwise determines.

3.2 Authority of the Committee.

(a) The Committee,

in its sole discretion, shall determine the Key Employees, Consultants and Directors to whom, and the time or times at which Awards will

be granted, the form and amount of each Award, the expiration date of each Award, the time or times within which the Awards may be exercised,

the cancellation of the Awards and the other limitations, restrictions, terms and conditions applicable to the grant of the Awards. The

terms and conditions of the Awards need not be the same with respect to each Participant or with respect to each Award.

(b) To the extent

permitted by applicable law, regulation, and rules of a stock exchange on which the Common Stock is listed or traded, the Committee may

delegate its authority to grant Awards to Key Employees and to determine the terms and conditions thereof to such officer of the Company

as it may determine in its discretion, on such terms and conditions as it may impose, except with respect to Awards to officers subject

to Section 16 of the Exchange Act.

may, subject to the provisions of the Plan, establish such rules and regulations as it deems necessary or advisable for the proper administration

of the Plan, and may make determinations and may take such other action in connection with or in relation to the Plan as it deems necessary

or advisable. Each determination or other action made or taken pursuant to the Plan, including interpretation of the Plan and the specific

terms and conditions of the Awards granted hereunder, shall be final and conclusive for all purposes and upon all persons.

(d) No member of

the Board or the Committee shall be liable for any action taken or determination made hereunder in good faith. Service on the Committee

shall constitute service as a Director so that the members of the Committee shall be entitled to indemnification and reimbursement as

Directors of the Company pursuant to the Company’s Amended and Restated Articles of Incorporation and Amended and Restated Bylaws.

3.3 Award Agreements.

(a) Each Award shall

be evidenced by a written Award Agreement specifying the terms and conditions of the Award. In the sole discretion of the Committee, the

Award Agreement may condition the grant of an Award upon the Participant’s entering into one or more of the following agreements

with the Company: (i) an agreement not to compete with the Company and its Subsidiaries which shall become effective as of the date of

the grant of the Award and remain in effect for a specified period of time following termination of the Participant’s employment

with the Company; (ii) an agreement to cancel any employment agreement, fringe benefit or compensation arrangement in effect between the

Company and the Participant; and (iii) an agreement to retain the confidentiality of certain information. Such agreements may contain

such other terms and conditions as the Committee shall determine. If the Participant shall fail to enter into any such agreement at the

request of the Committee, then the Award granted or to be granted to such Participant shall be forfeited and cancelled.

Section 4.

Shares of Common Stock Subject to Plan.

4.1 Total Number of Shares.

(a) The total number

of shares of Common Stock that may be issued under the Plan shall be 765,061 (which reflects the 115,061 shares previously authorized

under the Plan and 650,000 shares to be issued under the Plan pursuant to this amendment and restatement). Such shares may be either authorized

but unissued shares or treasury shares, and shall be adjusted in accordance with the provisions of Section 4.3 of the Plan.

(b) The number of

shares of Common Stock delivered by a Participant or withheld by the Company on behalf of any such Participant as full or partial payment

of an Award, including the exercise price of a Stock Option or of any required withholding taxes, shall not again be available for issuance

pursuant to subsequent Awards, and shall count towards the aggregate number of shares of Common Stock that may be issued under the Plan.

Any shares of Common Stock purchased by the Company with proceeds from a Stock Option exercise shall not again be available for issuance

pursuant to subsequent Awards, shall count against the aggregate number of shares that may be issued under the Plan and shall not increase

the number of shares available under the Plan.

a lapse, forfeiture, expiration, termination or cancellation of any Award for any reason (including for reasons described in Section 3.3),

or if shares of Common Stock are issued under such Award and thereafter are reacquired by the Company pursuant to rights reserved by the

Company upon issuance thereof, the shares of Common Stock subject to such Award or reacquired by the Company shall again be available

for issuance pursuant to subsequent Awards, and shall not count towards the aggregate number of shares of Common Stock that may be issued

under the Plan.

4.2 Shares Under Awards.

Of the shares of Common Stock

authorized for issuance under the Plan pursuant to Section 4.1:

(a) The maximum

number of shares of Common Stock as to which a Key Employee may receive Stock Options or SARs in any calendar year will not exceed $1,500,000

in total value (calculating the value of any such Stock Options or SARs based on the grant date fair value of such Stock Options or SARs

for financial reporting purposes). For the avoidance of doubt, shares of Common Stock that may be used for Stock Awards and/or Stock Unit

Awards pursuant to Section 4.2(c) shall not be included in the foregoing calculation.

(b) The maximum

number of shares of Common Stock that may be subject to Stock Options (ISOs and/or NSOs) is the total number of shares set forth in Section

4.1(a).

number of shares of Common Stock that may be used for Stock Awards and/or Stock Unit Awards that may be granted to any Key Employee in

any calendar year will not exceed $1,500,000 in total value (calculating the value of any such Stock Awards and/or Stock Unit Awards based

on the grant date fair value of such Stock Awards and/or Stock Unit Awards for financial reporting purposes). For the avoidance of doubt,

shares of Common Stock that may be used for Stock Options and/or SARs pursuant to Section 4.2(a) shall not be included in the foregoing

calculation.

(d) The maximum

number of shares of Common Stock subject to Awards granted under the Plan or otherwise during any one calendar year to any Director, taken

together with any cash fees paid by the Company to such Director during such calendar year for service on the Board, will not exceed $300,000

in total value (calculating the value of any such Awards based on the grant date fair value of such Awards for financial reporting purposes).

The numbers of shares described herein shall be

as adjusted in accordance with Section 4.3 of the Plan.

4.3 Adjustment.

In the event of any reorganization,

recapitalization, stock split, stock distribution, merger, consolidation, split-up, spin-off, combination, subdivision, consolidation

or exchange of shares, any change in the capital structure of the Company or any similar corporate transaction, the Committee shall make

such adjustments as it deems appropriate, in its sole discretion, to preserve the benefits or intended benefits of the Plan and Awards

granted under the Plan. Such adjustments may include: (a) adjustment in the number and kind of shares reserved for issuance under the

Plan; (b) adjustment in the number and kind of shares covered by outstanding Awards; (c) adjustment in the exercise price of outstanding

Stock Options or SARs or the price of Stock Awards or Stock Unit Awards under the Plan; (d) adjustments to any of the shares limitations

set forth in Section 4.1 or 4.2 of the Plan; and (e) any other changes that the Committee determines to be equitable under the circumstances.

Section 5.

Grants of Stock Options.

5.1 Grant.

Subject to the terms of the

Plan, the Committee may from time to time grant Stock Options to Participants. Unless otherwise expressly provided at the time of the

grant, Stock Options granted under the Plan to Key Employees will be NSOs. Stock Options granted under the Plan to Directors or Consultants

who, in each case are not employees of the Company or any Subsidiary will be NSOs.

5.2 Stock Option Agreement.

The grant of each Stock Option

shall be evidenced by a written Stock Option Agreement specifying the type of Stock Option granted, the exercise period, the exercise

price, the terms for payment of the exercise price, the expiration date of the Stock Option, the number of shares of Common Stock to be

subject to each Stock Option and such other terms and conditions established by the Committee, in its sole discretion, not inconsistent

with the Plan.

5.3 Exercise Price and Exercise Period.

With respect to each Stock

Option granted to a Participant:

(a) The per share

exercise price of each Stock Option shall be not less than the Fair Market Value of the Common Stock subject to the Stock Option on the

date on which the Stock Option is granted.

(b) Each Stock Option

shall become vest and exercisable as provided in the Stock Option Agreement; provided that the Committee shall have the discretion to

accelerate the date as of which any Stock Option shall become exercisable in the event of the Participant’s termination of employment

with the Company, or service on the Board or as a Consultant, without cause (as determined by the Board in its sole discretion).

or dividend equivalents shall be paid with respect to any shares subject to a Stock Option prior to the exercise of the Stock Option.

(d) Each Stock Option

shall expire, and all rights to purchase shares of Common Stock thereunder shall expire, on the date ten years after the date of grant.

5.4 Required Terms and

Conditions of ISOs.

In addition to the foregoing,

each ISO granted to a Key Employee shall be subject to the following specific rules:

(a) The aggregate

Fair Market Value (determined with respect to each ISO at the time such Option is granted) of the shares of Common Stock with respect

to which ISOs are exercisable for the first time by a Key Employee during any calendar year (under all incentive stock option plans of

the Company and its Subsidiaries) shall not exceed $100,000. If the aggregate Fair Market Value (determined at the time of grant) of the

Common Stock subject to an ISO which first becomes exercisable in any calendar year exceeds the limitation of this Section 5.4(a), so

much of the ISO that does not exceed the applicable dollar limit shall be an ISO and the remainder shall be a NSO; but in all other respects,

the original Stock Option Agreement shall remain in full force and effect.

(b) Notwithstanding

anything herein to the contrary, if an ISO is granted to a Key Employee who owns stock possessing more than 10% of the total combined

voting power of all classes of stock of the Company (or its parent or subsidiaries within the meaning of Section 422(b)(6) of the Code):

(i) the purchase price of each share of Common Stock subject to the ISO shall be not less than 110% of the Fair Market Value of the Common

Stock on the date the ISO is granted; and (ii) the ISO shall expire, and all rights to purchase shares of Common Stock thereunder shall

expire, no later than the fifth anniversary of the date the ISO was granted.

be granted under the Plan after ten years from the earlier of the date the Plan is adopted or approved by stockholders of the Company.

5.5 Exercise of Stock Options.

(a) A Participant

entitled to exercise a Stock Option may do so by delivering written notice to that effect specifying the number of shares of Common Stock

with respect to which the Stock Option is being exercised and any other information the Committee may prescribe. All notices or requests

provided for herein shall be delivered to the Chief Financial Officer of the Company.

(b) The Committee

in its sole discretion may make available one or more of the following alternatives for the payment of the Stock Option exercise price:

(i) in cash; (ii) in cash received from a broker-dealer to whom the Participant has submitted an exercise notice together with irrevocable

instructions to deliver promptly to the Company the amount of sales proceeds from the sale of the shares subject to the Stock Option to

pay the exercise price; (iii) by directing the Company to withhold such number of shares of Common Stock otherwise issuable in connection

with the exercise of the Stock Option having an aggregate Fair Market Value equal to the exercise price; (iv) by delivering previously

acquired shares of Common Stock that are acceptable to the Committee and that have an aggregate Fair Market Value on the date of exercise

equal to the Stock Option exercise price; (v) by certifying to ownership by attestation of such previously acquired shares of Common Stock;

or (vi) by combination of any of the foregoing methods.

The Committee shall have the

sole discretion to establish the terms and conditions applicable to any alternative made available for payment of the Stock Option exercise

price.

Section 6.

Stock Awards.

6.1 Grant.

The Committee may, in its

discretion, (a) grant shares of Common Stock under the Plan to any Participant without consideration from such Participant or (b) sell

shares of Common Stock under the Plan to any Participant for such amount of cash, Common Stock or other consideration as the Committee

deems appropriate.

6.2 Stock Award Agreement.

Each share of Common Stock

granted or sold hereunder shall be subject to such restrictions, conditions and other terms as the Board may determine at the time of

grant or sale, the general provisions of the Plan, the restrictions, terms and conditions of the related Stock Award Agreement, and the

following specific rules:

(a) The Award Agreement

shall specify whether the shares of Common Stock are granted or sold to the Participant and such other provisions, not inconsistent with

the terms and conditions of the Plan, as the Committee shall determine.

(b) The restrictions

to which the shares of Common Stock awarded hereunder are subject shall lapse as provided in Stock Award Agreement; provided that the

Committee shall have the discretion to accelerate the date as of which the restrictions lapse with respect to any Award held by a Participant

in the event of the Participant’s termination of employment with the Company, or service on the Board or as a Consultant, without

cause (as determined by the Committee in its sole discretion).

in this subsection (c) and unless otherwise set forth in the related Stock Award Agreement, the Participant receiving a grant of or purchasing

Common Stock pursuant to an Award Agreement shall thereupon be a stockholder with respect to such shares and shall have the rights of

a stockholder with respect to such shares, including the right to vote such shares and to receive dividends and other distributions paid

with respect to such shares; provided that any dividends or other distributions payable with respect to the Stock Award shall be accumulated

and held by the Company and paid to the Participant only upon, and to the extent, the restrictions lapse in accordance with the terms

of the applicable Stock Award Agreement. Any such dividends or other distributions held by the Company attributable to the portion of

a Stock Award that is forfeited shall also be forfeited.

Section 7.

Stock Unit Awards.

7.1 Grant.

The Committee may, in its

discretion, grant Stock Unit Awards to any Participant. Each Stock Unit subject to the Award shall entitle the Participant to receive,

on the date or the occurrence of an event (including the attainment of performance goals) as described in the Stock Unit Award Agreement,

a share of Common Stock or cash equal to the Fair Market Value of a share of Common Stock on such date or the date of such event as provided

in the Stock Unit Award Agreement.

7.2 Stock Unit Agreement.

Each Stock Unit Award shall

be subject to such restrictions, conditions and other terms as the Committee may determine at the time of grant, the general provisions

of the Plan, the restrictions, terms and conditions of the related Stock Unit Award Agreement and the following specific rules:

(a) The Stock Unit

Agreement shall specify such provisions, not inconsistent with the terms and conditions of the Plan, as the Committee shall determine.

(b) The restrictions

to which the shares of Stock Units awarded hereunder are subject shall lapse as provided in Stock Unit Agreement; provided that the Committee

shall have the discretion to accelerate the date as of which the restrictions lapse with respect to any Award held by a Participant in

the event of the Participant’s termination of employment with the Company, or service on the Board or as a Consultant, without cause

(as determined by the Board in its sole discretion).

in this subsection (c) and unless otherwise set forth in the Stock Unit Agreement, the Participant receiving a Stock Unit Award shall

have no rights of a stockholder, including voting or dividends or other distributions rights, with respect to any Stock Units prior to

the date they are settled in shares of Common Stock; provided that a Stock Unit Award Agreement may provide that until the Stock Units

are settled in shares or cash, the Participant shall be entitled to receive on each dividend or distribution payment date applicable to

the Common Stock an amount equal to the dividends or other distributions that the Participant would have received had the Stock Units

held by the Participant as of the related record date been actual shares of Common Stock. Such amounts shall be accumulated and held by

the Company and paid to the Participant only upon, and to the extent, the restrictions lapse in accordance with the terms of the applicable

Stock Unit Award Agreement. Such amounts held by the Company attributable to the portion of the Stock Unit Award that is forfeited shall

also be forfeited.

Section 8.

SARs.

8.1 Grant.

The Committee may grant SARs

to Participants. Upon exercise, an SAR entitles the Participant to receive from the Company the number of shares of Common Stock having

an aggregate Fair Market Value equal to the excess of the Fair Market Value of one share as of the date on which the SAR is exercised

over the exercise price, multiplied by the number of shares with respect to which the SAR is being exercised. The Committee, in its discretion,

shall be entitled to cause the Company to elect to settle any part or all of its obligations arising out of the exercise of an SAR by

the payment of cash in lieu of all or part of the shares it would otherwise be obligated to deliver in an amount equal to the Fair Market

Value of such shares on the date of exercise. Cash shall be delivered in lieu of any fractional shares. The terms and conditions of any

such Award shall be determined at the time of grant.

8.2 SAR Agreement.

(a) Each SAR shall

be evidenced by a written SAR Agreement specifying the terms and conditions of the SAR as the Committee may determine, including the SAR

exercise price, expiration date of the SAR, the number of shares of Common Stock to which the SAR pertains, the form of settlement and

such other terms and conditions established by the Committee, in its sole discretion, not inconsistent with the Plan.

(b) The per Share

exercise price of each SAR shall not be less than 100% of the Fair Market Value of a Share on the date the SAR is granted.

expire and all rights thereunder shall cease on the date fixed by the Committee in the related SAR Agreement, which shall not be later

than the ten years after the date of grant; provided however, if a Participant is unable to exercise an SAR because trading in the Common

Stock is prohibited by law or the Company’s insider-trading policy, the SAR exercise date shall be extended to the date that is

30 days after the expiration of the trading prohibition.

(d) Each SAR shall

become exercisable as provided in the related SAR Agreement; provided that notwithstanding any other Plan provision, the Committee shall

have the discretion to accelerate the date as of which any SAR shall become exercisable in the event of the Participant’s termination

of employment, or service on the Board or as a Consultant, without cause (as determined by the Committee in its sole discretion).

(e) No dividends

or dividend equivalents shall be paid with respect to any SAR prior to the exercise of the SAR.

(f) A person entitled

to exercise an SAR may do so by delivery of a written notice in accordance with procedures established by the Committee specifying the

number of shares of Common Stock with respect to which the SAR is being exercised and any other information the Committee may prescribe.

As soon as reasonably practicable after the exercise of an SAR, the Company shall (i) issue the total number of full shares of Common

Stock to which the Participant is entitled and cash in an amount equal to the Fair Market Value, as of the date of exercise, of any resulting

fractional share, and (ii) if the Committee causes the Company to elect to settle all or part of its obligations arising out of the exercise

of the SAR in cash, deliver to the Participant an amount in cash equal to the Fair Market Value, as of the date of exercise, of the shares

it would otherwise be obligated to deliver.

Section 9.

Change in Control.

9.1 Effect of a Change

in Control.

(a) Notwithstanding

any of the provisions of the Plan or any outstanding Award Agreement, upon a Change in Control of the Company (as defined in Section 9.2),

the Board is authorized and has sole discretion to provide that (i) all outstanding Awards shall become fully exercisable, (ii) all restrictions

applicable to all Awards shall terminate or lapse and (iii) performance goals applicable to any Awards shall be deemed satisfied at the

highest level, as applicable, in order that Participants may realize the benefits thereunder.

(b) In addition

to the Board’s authority set forth in Section 3, upon such Change in Control of the Company, the Board is authorized and has sole

discretion as to any Award, either at the time such Award is granted hereunder or any time thereafter, to take any one or more of the

following actions: (i) provide for the purchase of any outstanding Stock Option or SAR, for an amount of cash equal to the difference

between the exercise price and the then Fair Market Value of the Common Stock covered thereby had such Stock Option or SAR been currently

exercisable; (ii) make such adjustment to any such Award then outstanding as the Board deems appropriate to reflect such Change in Control;

and (iii) cause any such Award then outstanding to be assumed by the acquiring or surviving corporation after such Change in Control.

Without limiting the generality of the foregoing, in the case of any Stock Option or SAR with an exercise price that equals or exceeds

the fair market value of the per share consideration received by holders of Common Stock in the Change in Control, the Board may cancel

the Stock Option or SAR without the payment of consideration therefor.

9.2 Definition of Change

in Control.

“Change in Control”

of the Company shall be deemed to have occurred if at any time during the term of an Award granted under the Plan any of the following

events occurs:

(a) any Person (other

than the Company, a trustee or other fiduciary holding securities under an employee benefit plan of the Company, or a corporation owned

directly or indirectly by the stockholders of the Company in substantially the same proportions as their ownership of shares of Common

Stock of the Company) is or becomes the Beneficial Owner, directly or indirectly, of securities of the Company representing 30% or more

of the combined voting power of the Company’s then outstanding securities entitled to vote generally in the election of directors

(“Person” and “Beneficial Owner” being defined in Rule 13d-3 of the General Rules and Regulations of the Exchange

Act);

(b) the Company

is party to a merger, consolidation, reorganization or other similar transaction with another corporation or other Person unless, following

such transaction, more than 50% of the combined voting power of the outstanding securities of the surviving, resulting or acquiring corporation

or Person or its parent entity entitled to vote generally in the election of directors (or Persons performing similar functions) is then

beneficially owned, directly or indirectly, by all or substantially all of the individuals and entities who were the beneficial owners

of the Company’s outstanding securities entitled to vote generally in the election of directors immediately prior to such transaction,

in substantially the same proportions as their ownership, immediately prior to such transaction, of the Company’s outstanding securities

entitled to vote generally in the election of directors;

to the Board, without the recommendation or approval of two-thirds of the incumbent Board, of the lesser of: (i) three Directors; or (ii)

Directors constituting a majority of the number of Directors of the Company then in office; provided, however, that Directors whose initial

assumption of office is in connection with an actual or threatened election contest, including but not limited to a consent solicitation,

relating to the election of Directors of the Company will not be considered as incumbent members of the Board for purposes of this Section;

(d) there is a complete

liquidation or dissolution of the Company, or the Company sells all or substantially all of its business and/or assets to another corporation

or other Person unless, following such sale, more than 50% of the combined voting power of the outstanding securities of the acquiring

corporation or Person or its parent entity entitled to vote generally in the election of directors (or Persons performing similar functions)

is then beneficially owned, directly or indirectly, by all or substantially all of the individuals and entities who were the beneficial

owners of the Company’s outstanding securities entitled to vote generally in the election of directors immediately prior to such

sale, in substantially the same proportions as their ownership, immediately prior to such sale, of the Company’s outstanding securities

entitled to vote generally in the election of directors.

In no event, however, shall

a Change in Control be deemed to have occurred, with respect to a Participant, if that Participant is part of a purchasing group which

consummates the Change in Control transaction. A Participant shall be deemed “part of a purchasing group” for purposes of

the preceding sentence if the Participant is an equity participant or has agreed to become an equity participant in the purchasing company

or group (except for (a) passive ownership of less than 3% of the shares of the purchasing company; or (b) ownership of equity participation

in the purchasing company or group which is otherwise not deemed to be significant, as determined prior to the Change in Control by a

majority of the disinterested Directors).

Section 10.

Payment of Taxes.

(a) In connection

with any Award, and as a condition to the issuance or delivery of any shares of Common Stock to the Participant in connection therewith,

the Company shall require the Participant to pay the Company the minimum amount of federal, state, local or foreign taxes required to

be withheld, and in the Company’s sole discretion, the Company may permit the Participant to pay the Company up to the maximum individual

statutory rate of applicable withholding.

(b) The Company

in its sole discretion may make available one or more of the following alternatives for the payment of such taxes: (i) in cash; (ii) in

cash received from a broker-dealer to whom the Participant has submitted notice together with irrevocable instructions to deliver promptly

to the Company the amount of sales proceeds from the sale of the shares subject to the Award to pay the withholding taxes; (iii) by directing

the Company to withhold such number of shares of Common Stock otherwise issuable in connection with the Award having an aggregate Fair

Market Value equal to the minimum amount of tax required to be withheld; (iv) by delivering previously acquired shares of Common Stock

of the Company that are acceptable to the Board that have an aggregate Fair Market Value equal to the amount required to be withheld;

or (v) by certifying to ownership by attestation of such previously acquired shares of Common Stock.

The Committee shall have the sole discretion to

establish the terms and conditions applicable to any alternative made available for payment of the required withholding taxes.

Section 11.

Postponement.

The Committee may postpone

any grant or settlement of an Award or exercise of a Stock Option or SAR for such time as the Board in its sole discretion may deem necessary

in order to permit the Company:

(a) to effect, amend

or maintain any necessary registration of the Plan or the shares of Common Stock issuable pursuant to an Award, including upon the exercise

of a Stock Option or SAR, under the Securities Act of 1933, as amended, or the securities laws of any applicable jurisdiction;

(b) to permit any

action to be taken in order to (i) list such shares of Common Stock on a stock exchange if shares of Common Stock are then listed on such

exchange or (ii) comply with restrictions or regulations incident to the maintenance of a public market for its shares of Common Stock,

including any rules or regulations of any stock exchange on which the shares of Common Stock are listed; or

that such shares of Common Stock and the Plan are exempt from such registration or that no action of the kind referred to in (b)(ii) above

needs to be taken; and the Company shall not be obligated by virtue of any terms and conditions of any Award or any provision of the Plan

to sell or issue shares of Common Stock in violation of the Securities Act of 1933 or the law of any government having jurisdiction thereof.

Any such postponement shall not extend the term

of an Award and neither the Company nor its Directors or officers shall have any obligation or liability to a Participant, the Participant’s

successor or any other person with respect to any shares of Common Stock as to which the Award shall lapse because of such postponement.

Section 12.

Nontransferability.

Awards granted under the Plan, and any rights

and privileges pertaining thereto, may not be transferred, assigned, pledged or hypothecated in any manner, or be subject to execution,

attachment or similar process, by operation of law or otherwise, other than by will or by the laws of descent and distribution.

Section 13.

Delivery of Shares.

Shares of Common Stock issued pursuant to a Stock

Award, the exercise of a Stock or SAR or the settlement of a Stock Unit Award shall be represented by stock certificates or on a non-certificated

basis, with the ownership of such shares by the Participant evidenced solely by book entry in the records of the Company’s transfer

agent; provided, however, that upon the written request of the Participant, the Company shall issue, in the name of the Participant, stock

certificates representing such shares of Common Stock. Notwithstanding the foregoing, shares granted pursuant to a Stock Award shall be

held by the Secretary of the Company until such time as the shares are forfeited or settled.

Section 14.

Termination or Amendment of Plan and Award Agreements.

14.1 Termination or Amendment

of Plan.

(a) Except as described

in Section 14.3 below, the Board may terminate, suspend, or amend the Plan, in whole or in part, from time to time, without the approval

of the stockholders of the Company, unless such approval is required by applicable law, regulation or rule of any stock exchange on which

the shares of Common Stock are listed. No amendment or termination of the Plan shall adversely affect the right of any Participant under

any outstanding Award in any material way without the written consent of the Participant, unless such amendment or termination is required

by applicable law, regulation or rule of any stock exchange on which the shares of Common Stock are listed. Subject to the foregoing,

the Committee may correct any defect or supply an omission or reconcile any inconsistency in the Plan or in any Award granted hereunder

in the manner and to the extent it shall deem desirable, in its sole discretion, to effectuate the Plan.

(b) The Board shall

have the authority to amend the Plan to the extent necessary or appropriate to comply with applicable law, regulation or accounting rules

in order to permit Participants who are located outside of the United States to participate in the Plan.

14.2 Amendment of Award

Agreements.

The Committee shall have the

authority to amend any Award Agreement at any time; provided however, that no such amendment shall adversely affect the right of any Participant

under any outstanding Award Agreement in any material way without the written consent of the Participant, unless such amendment is required

by applicable law, regulation or rule of any stock exchange on which the shares of Common Stock are listed.

14.3 No Repricing of Stock Options.

Notwithstanding the foregoing,

and except as described in Section 4.3, there shall be no amendment to the Plan or any outstanding Stock Option Agreement or SAR Agreement

that results in the repricing of Stock Options or SARs without stockholder approval. For this purpose, repricing includes (i) a reduction

in the exercise price of the Stock Option or SARs or (ii) the cancellation of a Stock Option in exchange for cash, Stock Options or SARs

with an exercise price less than the exercise price of the cancelled Options or SARs, other Awards or any other consideration provided

by the Company, but does not include any adjustment described in Section 4.3.

Section 15.

No Contract of Employment.

Neither the adoption of the

Plan nor the grant of any Award under the Plan shall be deemed to obligate the Company or any Subsidiary to continue the employment or

service of any Participant for any particular period, nor shall the granting of an Award constitute a request or consent to postpone the

retirement date of any Participant.

Section 16.

Applicable Law.

All questions pertaining to

the validity, construction and administration of the Plan and all Awards granted under the Plan shall be determined in conformity with

the laws of the State of Nevada, without regard to the conflict of law provisions of any state, and, in the case of Incentive Stock Options,

Section 422 of the Code and regulations issued thereunder.

Section 17.

Effective Date and Term of Plan.

17.1 Effective Date.

(a) The Plan was

initially approved by the stockholders of the Company on April 6, 2020.

(b) The Plan as

amended and restated has been adopted by the Board, and is effective, as of September 30, 2026, subject to the approval of the Plan by

the stockholders of the Company.

the Plan is not approved by stockholders of the Company within 12 months of the date hereof, the Plan as amended and restated shall have

no effect, and the Plan as in effect prior to September 30, 2026 shall continue.

17.2 Term of Plan.

Notwithstanding anything to

the contrary contained herein, no Awards shall be granted on or after April 6, 2030.

XML — IDEA: XBRL DOCUMENT

XML

Filename: R1.htm · Sequence: 7

v3.26.3

Cover

Sep. 30, 2026

Cover [Abstract]

Document Type

8-K

Amendment Flag

false

Document Period End Date

Sep. 30, 2026

Entity File Number

001-39126

Entity Registrant Name

CNS Pharmaceuticals, Inc.

Entity Central Index Key

0001729427

Entity Tax Identification Number

82-2318545

Entity Incorporation, State or Country Code

Entity Address, Address Line One

2100 West Loop South

Entity Address, Address Line Two

Suite 900

Entity Address, City or Town

Houston

Entity Address, State or Province

Entity Address, Postal Zip Code

77027

City Area Code

(800)

Local Phone Number

946-9185

Written Communications

false

Soliciting Material

false

Pre-commencement Tender Offer

false

Pre-commencement Issuer Tender Offer

false

Title of 12(b) Security

Common stock, par value $0.001 per share

Trading Symbol

CNSP

Security Exchange Name

NASDAQ

Entity Emerging Growth Company

false

Entity Information, Former Legal or Registered Name

Not Applicable

- Definition

Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.

+ References

No definition available.

+ Details

Name:

dei_AmendmentFlag

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Area code of city

+ References

No definition available.

+ Details

Name:

dei_CityAreaCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Cover page.

+ References

No definition available.

+ Details

Name:

dei_CoverAbstract

Namespace Prefix:

dei_

Data Type:

xbrli:stringItemType

Balance Type:

Period Type:

duration

- Definition

For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.

+ References

No definition available.

+ Details

Name:

dei_DocumentPeriodEndDate

Namespace Prefix:

dei_

Data Type:

xbrli:dateItemType

Balance Type:

Period Type:

duration

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.

+ References

No definition available.

+ Details

Name:

dei_DocumentType

Namespace Prefix:

dei_

Data Type:

dei:submissionTypeItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 1 such as Attn, Building Name, Street Name

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine1

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 2 such as Street or Suite number

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine2

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the City or Town

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCityOrTown

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Code for the postal or zip code

+ References

No definition available.

+ Details

Name:

dei_EntityAddressPostalZipCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the state or province.

+ References

No definition available.

+ Details

Name:

dei_EntityAddressStateOrProvince

Namespace Prefix:

dei_

Data Type:

dei:stateOrProvinceItemType

Balance Type:

Period Type:

duration

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityCentralIndexKey

Namespace Prefix:

dei_

Data Type:

dei:centralIndexKeyItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if registrant meets the emerging growth company criteria.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityEmergingGrowthCompany

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.

+ References

No definition available.

+ Details

Name:

dei_EntityFileNumber

Namespace Prefix:

dei_

Data Type:

dei:fileNumberItemType

Balance Type:

Period Type:

duration

- Definition

Two-character EDGAR code representing the state or country of incorporation.

+ References

No definition available.

+ Details

Name:

dei_EntityIncorporationStateCountryCode

Namespace Prefix:

dei_

Data Type:

dei:edgarStateCountryItemType

Balance Type:

Period Type:

duration

- Definition

Former Legal or Registered Name of an entity

+ References

No definition available.

+ Details

Name:

dei_EntityInformationFormerLegalOrRegisteredName

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityRegistrantName

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityTaxIdentificationNumber

Namespace Prefix:

dei_

Data Type:

dei:employerIdItemType

Balance Type:

Period Type:

duration

- Definition

Local phone number for entity.

+ References

No definition available.

+ Details

Name:

dei_LocalPhoneNumber

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 13e

-Subsection 4c

+ Details

Name:

dei_PreCommencementIssuerTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14d

-Subsection 2b

+ Details

Name:

dei_PreCommencementTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Title of a 12(b) registered security.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b

+ Details

Name:

dei_Security12bTitle

Namespace Prefix:

dei_

Data Type:

dei:securityTitleItemType

Balance Type:

Period Type:

duration

- Definition

Name of the Exchange on which a security is registered.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection d1-1

+ Details

Name:

dei_SecurityExchangeName

Namespace Prefix:

dei_

Data Type:

dei:edgarExchangeCodeItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14a

-Subsection 12

+ Details

Name:

dei_SolicitingMaterial

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name:

dei_TradingSymbol

Namespace Prefix:

dei_

Data Type:

dei:tradingSymbolItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 230

-Section 425

+ Details

Name:

dei_WrittenCommunications

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration